Rho/PAK signaling: a key driver of anthracycline and taxane resistance in breast cancer.
2/5 보강
OpenAlex 토픽 ·
Protein Kinase Regulation and GTPase Signaling
Cancer Treatment and Pharmacology
Melanoma and MAPK Pathways
Resistance to anthracyclines and taxanes remains a major barrier to effective breast cancer treatment, particularly in aggressive subtypes such as triple-negative breast cancer.
APA
Nurul Syafawani Fizal, Nik Yasmin Umaira Hasnizan, et al. (2026). Rho/PAK signaling: a key driver of anthracycline and taxane resistance in breast cancer.. Medical oncology (Northwood, London, England), 43(6). https://doi.org/10.1007/s12032-026-03294-7
MLA
Nurul Syafawani Fizal, et al.. "Rho/PAK signaling: a key driver of anthracycline and taxane resistance in breast cancer.." Medical oncology (Northwood, London, England), vol. 43, no. 6, 2026.
PMID
42033530 ↗
Abstract 한글 요약
Resistance to anthracyclines and taxanes remains a major barrier to effective breast cancer treatment, particularly in aggressive subtypes such as triple-negative breast cancer. Although these agents form the backbone of systemic chemotherapy, variability in response limits long-term survival benefits and underscores the urgent need for predictive biomarkers and novel therapeutic strategies. Emerging evidence implicates Rho family small GTPases and their downstream effectors, p21-activated kinases (PAKs), as central regulators of cytoskeletal remodeling, epithelial-mesenchymal transition, and survival signaling. Aberrant activation of the Rho/PAK axis enhances tumor cell adaptability through cross-talk with PI3K/AKT, MAPK, and NF-κB pathways, promoting DNA repair, apoptosis evasion, and multidrug efflux via P-glycoprotein. These mechanisms converge to reduce chemosensitivity, drive recurrence, and worsen patient outcomes. This review synthesizes current evidence linking Rho/PAK signaling with chemotherapy resistance, discusses its potential as a predictive biomarker for patient stratification, and explores therapeutic opportunities to restore chemosensitivity. Integrating molecular insights into clinical strategies may enable more effective, personalized treatment approaches in breast cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.